Signia to Introduce Aspire 3.0 Loyalty Program to Hearing Care Professionals

The reimagined Signia Aspire 3.0 program, launching in early 2022, will include new benefits and professional development opportunities for any practice at any stage of growth

Hearing aid innovator Signia today announced it will preview Signia Aspire 3.0, the most significant update to its industry-leading loyalty benefits program, designed to help hearing care professionals (HCPs) meet their business goals regardless of practice size.

Signia will present Aspire 3.0 to the HCP community at a special online event being held Oct. 26 at 12 PM EDT. All HCPs who attend, whether they are considering joining Aspire or are already a member, can earn 1,000 Aspire points and learn how to customize their Aspire experience to best support their practice. For more information and to register, HCPs can visit here.

Signia will officially launch Aspire 3.0 in early 2022.

HCPs become eligible for Aspire 3.0 by fitting patients with Signia hearing aids, unlocking access to a growing list of baseline benefits, such as consumer marketing funds, Signia-generated patient leads, a dedicated customer service number, free shipping, and more. As an Aspire member enhances human performance for more patients with Signia hearing aids, certain benefits grow with them.

Members of Aspire 3.0 earn points for every qualified order, which they can use in the Aspire store for items like audiological supplies, office equipment, Signia products, and other needs.

“But the new Aspire 3.0 is not merely a points program, nor is it a pricing program,” said Jennifer Wright, Senior Director of Partner Marketing. “It is a partnership program to help HCPs build their practices. We’re delivering these benefits so HCPs can strengthen their clinics, save time, and maximize patient visits.”

Through the newly designed Aspire 3.0 portal, HCPs will have exclusive access to tools that help them stay atop trends and technologies, a dashboard for tracking leads, easy access to their benefits, and opportunities to unlock an even richer Aspire 3.0 experience.

“We created Aspire 3.0 to be the exact opposite of one-size-fits-all,” Wright continued. “This new program was developed to deliver benefits that can help any practice, small or large. And as a practice grows, so can its access to Aspire programs and features, allowing HCPs to continually differentiate themselves, stand apart from their competition, and grow professionally within the communities they serve.”

Beyond the baseline benefits, Aspire members can qualify for and choose from various available Bonus Benefits, such as extra co-op dollars, points, or rebates, depending on their type of membership. Plus, Aspire members can take advantage of services to support their business, such as supplemental insurance for themselves and their employees, financing discounts, financial investment options, access to online business services, and more.

“As practices grow, they can have a deeper, more beneficial relationship with the Aspire program and our partners,” Wright concluded. “Through available bonus benefits, HCPs can really go higher with Aspire.”

For more information on Signia Aspire 3.0 or to become a member, click here or contact your local Signia team.


Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  

By using this website you agree to accept Medical Device News Magazine Privacy Policy